-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, major multinational pharmaceutical giants such as Pfizer, Merck, Johnson & Johnson, Roche, AbbVie, Merck, Novartis, GSK, Sanofi, Bristol-Myers Squibb and Amgen and other pharmaceutical manufacturers have released their third quarter 2021 financial reports.
.
Among them, Pfizer and Merck have outstanding performance, with growth rates of 130% and 19% respectively
.
According to Pfizer’s recently announced third-quarter performance data for 2021, Pfizer achieved revenue of US$24.
1 billion in the third quarter, a year-on-year increase of over 130%
.
The third quarter report shows that Pfizer's total revenue in the first three quarters was US$57.
7 billion, a year-on-year increase of 91%
.
The reason is that Pfizer successfully cooperated with BioNTech to develop vaccines.
Its vaccines' global sales in the third quarter exceeded 13 billion U.
S.
dollars, which also helped Pfizer achieve an astonishing 130% year-on-year growth in the third quarter of 2021
.
According to Merck’s third-quarter 2021 results, Merck’s Q3 sales were US$13.
154 billion, an increase of 20% year-on-year; GAAP net profit was US$4.
567 billion, a year-on-year increase of 55%
.
By business, sales of the pharmaceutical business increased by 18% year-on-year to US$11.
496 billion
.
Among them, the sales of anti-cancer drug Keytruda increased by 22% year-on-year to US$4.
534 billion; sales of GARDASIL/GARDASIL 9 (HPV vaccine) increased by 68% year-on-year to US$1.
993 billion; sales of diabetes drug JANUVIA/JANUMET The amount increased by only 1% year-on-year to US$1.
339 billion
.
Animal health business sales increased by 16% year-on-year to US$1.
417 billion
.
According to financial report data, Merck’s third-quarter sales revenue mainly came from Keytruda (US$4.
5 billion) and HPV vaccine Gardasil (US$2 billion).
Sales of these two drugs alone accounted for 49% of total sales in the third quarter
.
It can be seen from the three quarterly reports of Pfizer and Merck that these two companies performed outstandingly in the third quarter..
So how about Roche's third-quarter performance, which sits firmly on the top spot in the IVD field? It is reported that according to Roche's new financial report, in the first three quarters of 2021, Roche's total revenue increased by 6% year-on-year to 46.
68 billion Swiss francs (approximately 325.
397 billion yuan)
.
The rise in its performance was mainly due to the rise in Roche's diagnostics business and the recovery in the pharmaceutical sector
.
Among them, the total revenue of Roche Diagnostics in the first three quarters increased by 38% year-on-year to 13.
305 billion Swiss francs (approximately 92.
746 billion yuan).
From a single quarter, Roche Diagnostics sales increased by 18% in the third quarter
.
In the pharmaceutical sector, revenue in the first three quarters was 33.
379 billion Swiss francs (approximately 232.
678 billion yuan), which was basically the same as last year's performance year-on-year
.
Next, let's look at Merck's performance in the third quarter
.
According to an announcement issued by Merck, the company's global sales in the third quarter increased by 20% from 10.
93 billion US dollars in the same period last year to 13.
15 billion US dollars
.
Among them, pharmaceutical sales increased 8% to 11.
50 billion U.
S.
dollars, KEYTRUDA sales increased 22% to 4.
5 billion U.
S.
dollars, GARDASIL/GARDASIL 9 increased 68% to 1.
99 billion U.
S.
dollars, and Januvia/JANUMET sales increased 1% compared to last year.
To 1.
34 billion US dollars
.
In addition, Novartis’s net sales in the third quarter were US$13.
303 billion, compared with US$12.
259 billion in the same period last year, an increase of 6% year-on-year; net profit was US$2.
758 billion, compared with US$1.
932 billion in the same period last year, a year-on-year increase of 43%; operating income was 32.
33 billion US dollars.
Billion U.
S.
dollars, compared with 2.
412 billion U.
S.
dollars in the same period last year, a year-on-year increase of 34%
.
According to the third quarter report data released by these companies, many multinational pharmaceutical companies have submitted satisfactory answers in the third quarter
.
According to the industry, even a few companies whose growth rate was late in the quarter, such as Roche, Novartis and Amgen, reached 8%, 6%, and 4% respectively
.
.
Among them, Pfizer and Merck have outstanding performance, with growth rates of 130% and 19% respectively
.
According to Pfizer’s recently announced third-quarter performance data for 2021, Pfizer achieved revenue of US$24.
1 billion in the third quarter, a year-on-year increase of over 130%
.
The third quarter report shows that Pfizer's total revenue in the first three quarters was US$57.
7 billion, a year-on-year increase of 91%
.
The reason is that Pfizer successfully cooperated with BioNTech to develop vaccines.
Its vaccines' global sales in the third quarter exceeded 13 billion U.
S.
dollars, which also helped Pfizer achieve an astonishing 130% year-on-year growth in the third quarter of 2021
.
According to Merck’s third-quarter 2021 results, Merck’s Q3 sales were US$13.
154 billion, an increase of 20% year-on-year; GAAP net profit was US$4.
567 billion, a year-on-year increase of 55%
.
By business, sales of the pharmaceutical business increased by 18% year-on-year to US$11.
496 billion
.
Among them, the sales of anti-cancer drug Keytruda increased by 22% year-on-year to US$4.
534 billion; sales of GARDASIL/GARDASIL 9 (HPV vaccine) increased by 68% year-on-year to US$1.
993 billion; sales of diabetes drug JANUVIA/JANUMET The amount increased by only 1% year-on-year to US$1.
339 billion
.
Animal health business sales increased by 16% year-on-year to US$1.
417 billion
.
According to financial report data, Merck’s third-quarter sales revenue mainly came from Keytruda (US$4.
5 billion) and HPV vaccine Gardasil (US$2 billion).
Sales of these two drugs alone accounted for 49% of total sales in the third quarter
.
It can be seen from the three quarterly reports of Pfizer and Merck that these two companies performed outstandingly in the third quarter..
So how about Roche's third-quarter performance, which sits firmly on the top spot in the IVD field? It is reported that according to Roche's new financial report, in the first three quarters of 2021, Roche's total revenue increased by 6% year-on-year to 46.
68 billion Swiss francs (approximately 325.
397 billion yuan)
.
The rise in its performance was mainly due to the rise in Roche's diagnostics business and the recovery in the pharmaceutical sector
.
Among them, the total revenue of Roche Diagnostics in the first three quarters increased by 38% year-on-year to 13.
305 billion Swiss francs (approximately 92.
746 billion yuan).
From a single quarter, Roche Diagnostics sales increased by 18% in the third quarter
.
In the pharmaceutical sector, revenue in the first three quarters was 33.
379 billion Swiss francs (approximately 232.
678 billion yuan), which was basically the same as last year's performance year-on-year
.
Next, let's look at Merck's performance in the third quarter
.
According to an announcement issued by Merck, the company's global sales in the third quarter increased by 20% from 10.
93 billion US dollars in the same period last year to 13.
15 billion US dollars
.
Among them, pharmaceutical sales increased 8% to 11.
50 billion U.
S.
dollars, KEYTRUDA sales increased 22% to 4.
5 billion U.
S.
dollars, GARDASIL/GARDASIL 9 increased 68% to 1.
99 billion U.
S.
dollars, and Januvia/JANUMET sales increased 1% compared to last year.
To 1.
34 billion US dollars
.
In addition, Novartis’s net sales in the third quarter were US$13.
303 billion, compared with US$12.
259 billion in the same period last year, an increase of 6% year-on-year; net profit was US$2.
758 billion, compared with US$1.
932 billion in the same period last year, a year-on-year increase of 43%; operating income was 32.
33 billion US dollars.
Billion U.
S.
dollars, compared with 2.
412 billion U.
S.
dollars in the same period last year, a year-on-year increase of 34%
.
According to the third quarter report data released by these companies, many multinational pharmaceutical companies have submitted satisfactory answers in the third quarter
.
According to the industry, even a few companies whose growth rate was late in the quarter, such as Roche, Novartis and Amgen, reached 8%, 6%, and 4% respectively
.
